Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
Beginning of a U.S. clinical study intended to secure U.S. FDA regulatory approval of the PROGENSA PCA3 assay
News
- January 14, 2010 - DiagnoCure announces fourth quarter 2009 and year-end results

- January 5, 2010 - DiagnoCure to host Q4 2009 and full year earnings conference call and webcast

Events
-
March 3 - 7, 2010
2010 SSO Annual Cancer Symposium
St. Louis, Missouri, USA
|
1.06
-0.01
|
Open: 1.05 $CAN.
Quotes are delayed.
|


